Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5-17
Description
Extended intervals between the first and second doses of mRNA Covid-19 vaccines may reduce the risk of myocarditis in children and adolescents. However, vaccine effectiveness after this extension remains unclear. To examine this potential variable